Microvascular Therapeutics, LCC

MVT has developed a new, patented formulation, MVT-100, for use as an ultrasound contrast agent. Compared to Definity®, MVT-100 may afford potential for room temperature storage, where Definity® requires refrigerated storage. MVT-100 has a neutral surface chemistry, potentially serving as a platform for development of agents for molecular imaging and image-guided therapy. We`ve received formal guidance from the FDA that MVT-100 can be developed via the 505(b)(2) pathway. The Company has designed an accelerated development pathway to potentially lead to approval of MVT-100 for echocardiography.